Viridian Therapeutics, Inc./DE Proceeds from Long-Term Debt Issued
Viridian Therapeutics, Inc./DE (VRDN) reported Proceeds from Long-Term Debt Issued of $28.88 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-02-26
- Viridian Therapeutics, Inc./DE proceeds from issuance of long-term debt for the quarter ending 2024-12-31 was $0.00.
- Viridian Therapeutics, Inc./DE proceeds from issuance of long-term debt for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE proceeds from issuance of long-term debt for the quarter ending 2023-09-30 was $15.00M.
- Viridian Therapeutics, Inc./DE proceeds from issuance of long-term debt for the quarter ending 2022-12-31 was $446.00K.
- Viridian Therapeutics, Inc./DE proceeds from issuance of long-term debt for fiscal 2025 was $28.88M.
- Viridian Therapeutics, Inc./DE proceeds from issuance of long-term debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Viridian Therapeutics, Inc./DE proceeds from issuance of long-term debt for fiscal 2023 was $15.00M, a 200.00% increase from fiscal 2022.
- Viridian Therapeutics, Inc./DE proceeds from issuance of long-term debt for fiscal 2022 was $5.00M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $28.88M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.00M derived: sum of 2 quarters · filed 2026-02-26 | $15.00M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $15.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $15.00M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $446.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $446.00K derived: sum of 2 quarters · filed 2025-03-03 | $5.00M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $4.55M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $4.55M 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |